Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors

Investigational New Drugs

Volumn 33, Issue 3, 2015, Pages 691-699

  Diamond, Jennifer R ^a   Wu, Benjamin ^b   Agarwal, Neeraj ^c   Bowles, Daniel W ^a   Lam, Elaine T ^a   Werner, Theresa L ^c   Rasmussen, Erik ^b   Gamelin, Erick ^b   Soto, Felipe ^b   Friberg, Greg ^b   Sun, Yu Nien ^b   Sharma, Sunil ^c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b AMGEN INC   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis inhibitors; Angiopoietin; Paclitaxel; Pharmacokinetic drug drug interaction; Trebananib

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; HYBRID PROTEIN; PACLITAXEL; TREBANANIB;

ADULT; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; CANCER STAGING; CLINICAL TRIAL; DEMOGRAPHY; DRUG INTERACTION; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NEOPLASMS; PATHOLOGY; PHASE 1 CLINICAL TRIAL; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEMOGRAPHY; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PACLITAXEL; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 84937762677     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-015-0236-4     Document Type: Article

References (19)

1. Monk BJ, Poveda A, Vergote IB, Raspagliesi F, Fujiwara K, Bae D-S, Oaknin A, Navale L, Warner DJ, Oza AM (2013) A phase 3, randomized, double-blind trial of weekly paclitaxel plus the angiopoietin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer: TRINOVA-1. Eur J Cancer 49(suppl 3):LBA 41
2. Coxon A, Bready J, Min H, Kaufman S, Leal J, Yu D, Lee TA, Sun JR, Estrada J, Bolon B, McCabe J, Wang L, Rex K, Caenepeel S, Hughes P, Cordover D, Kim H, Han SJ, Michaels ML, Hsu E, Shimamoto G, Cattley R, Hurh E, Nguyen L, Wang SX, Ndifor A, Hayward IJ, Falcon BL, McDonald DM, Li L, Boone T, Kendall R, Radinsky R, Oliner JD (2010) Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol Cancer Ther 9(10):2641-2651. doi: 10.1158/1535-7163.MCT-10-02139/10/2641
3. Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, Rasmussen E, Sun YN, Zhong D, Hwang YC, Evelhoch JL, Oliner JD, Le N, Rosen LS (2009) Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 27(21):3557-3565. doi: 10.1200/JCO.2008.19.6683
4. Wu B, Johnson J, Soto M, Ponce M, Calamba D, Sun YN (2012) Investigation of the mechanism of clearance of AMG 386, a selective angiopoietin-1/2 neutralizing peptibody, in splenectomized, nephrectomized, and FcRn knockout rodent models. Pharm Res 29(4):1057-1065. doi: 10.1007/s11095-011-0650-z
5. Lu JF, Rasmussen E, Karlan BY, Vergote IB, Navale L, Kuchimanchi M, Melara R, Stepan DE, Weinreich DM, Sun YN (2012) Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection. Cancer Chemother Pharmacol 69(5):1135-1144. doi: 10.1007/s00280-011-1787-5
6. Sonnichsen DS, Liu Q, Schuetz EG, Schuetz JD, Pappo A, Relling MV (1995) Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther 275(2):566-575
7. Jover R, Bort R, Gomez-Lechon MJ, Castell JV (2002) Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved. FASEB J 16(13):1799-1801. doi: 10.1096/fj.02-0195fje02-0195fje
8. Dickmann LJ, Patel SK, Rock DA, Wienkers LC, Slatter JG (2011) Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture. Drug Metab Dispos 39(8):1415-1422. doi: 10.1124/dmd.111.038679
9. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228-247. doi: 10.1016/j.ejca.2008.10.026
10. Weeraratne DK, Lofgren J, Dinnogen S, Swanson SJ, Zhong ZD (2013) Development of a biosensor-based immunogenicity assay capable of blocking soluble drug target interference. J Immunol Methods 396(1-2):44-55. doi: 10.1016/j.jim.2013.07.010
11. V3.0 C (Accessed 01 August 2014) http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf.
12. Ohtsu T, Sasaki Y, Tamura T, Miyata Y, Nakanomyo H, Nishiwaki Y, Saijo N (1995) Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-h infusion versus a 24-h infusion. Clin Cancer Res 1(6):599-606
13. Tanabe Y, Hashimoto K, Shimizu C, Hirakawa A, Harano K, Yunokawa M, Yonemori K, Katsumata N, Tamura K, Ando M, Kinoshita T, Fujiwara Y (2013) Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. Int J Clin Oncol 18(1):132-138. doi: 10.1007/s10147-011-0352-x
14. Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, Brem H (2007) Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf 6(5):609-621. doi: 10.1517/14740338.6.5.609
15. Karlan BY, Oza AM, Richardson GE, Provencher DM, Hansen VL, Buck M, Chambers SK, Ghatage P, Pippitt CH Jr, Brown JV 3rd, Covens A, Nagarkar RV, Davy M, Leath CA 3rd, Nguyen H, Stepan DE, Weinreich DM, Tassoudji M, Sun YN, Vergote IB (2012) Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 30(4):362-371. doi: 10.1200/JCO.2010.34.3178
16. Eatock MM, Tebbutt NC, Bampton CL, Strickland AH, Valladares-Ayerbes M, Swieboda-Sadlej A, Van Cutsem E, Nanayakkara N, Sun YN, Zhong ZD, Bass MB, Adewoye AH, Bodoky G (2013) Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. Ann Oncol 24(3):710-718. doi: 10.1093/annonc/mds502
17. Peeters M, Strickland AH, Lichinitser M, Suresh AV, Manikhas G, Shapiro J, Rogowski W, Huang X, Wu B, Warner D, Jain R, Tebbutt NC (2013) A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma. Br J Cancer 108(3):503-511. doi: 10.1038/bjc.2012.594 bjc2012594
18. Monk BJ, Minion L, Lambrechts S, Vergote IB, Devoogdt N, Karlan BY (2013) Incidence and management of edema associated with trebananib (AMG 386). Gynecol Oncol 130(3):636-641. doi: 10.1016/j.ygyno.2013.05.023
19. Rini B, Szczylik C, Tannir NM, Koralewski P, Tomczak P, Deptala A, Dirix LY, Fishman M, Ramlau R, Ravaud A, Rogowski W, Kracht K, Sun YN, Bass MB, Puhlmann M, Escudier B (2012) AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. Cancer 118(24):6152-6161. doi: 10.1002/cncr.27632